Efficacy of vitamin A in reducing preschool child mortality in Nepal

K P West1, R P Pokhrel, J Katz

  • 1Dana Center for Preventive Ophthalmology, Wilmer Eye Institute, Baltimore, Maryland 21205.

PubMed

Insights

Vitamin A supplementation significantly reduces preschool child mortality by 30% in developing countries. This finding from a Nepal trial resolves conflicting evidence on vitamin A

Area of Science:

  • Public Health
  • Nutritional Science
  • Pediatrics

Background:

  • Conflicting results from community trials on vitamin A supplementation's impact on preschool child mortality.
  • Need for definitive evidence to guide public health interventions.

Purpose of the Study:

  • To resolve conflicting evidence regarding the efficacy of vitamin A supplementation in reducing preschool child mortality.
  • To provide robust data on the impact of vitamin A on child survival in a representative South Asian population.

Main Methods:

  • A randomized, double-masked, placebo-controlled community trial involving 28,630 children aged 6-72 months in rural Nepal.
  • Children received either vitamin A (60,000 retinol equivalents) or placebo every 4 months.
  • Randomization was conducted at the administrative ward level.

Main Results:

  • A 30% reduction in mortality was observed in the vitamin A-supplemented group compared to the placebo group (Relative Risk = 0.70; 95% CI: 0.56-0.88) after 12 months.
  • Mortality reduction was consistent across sexes, all age groups (6-72 months), and throughout the year.
  • The benefit was independent of acute nutritional status, measured by arm circumference.

Conclusions:

  • Periodic community-based vitamin A supplementation is a highly effective strategy for reducing child mortality in developing countries.
  • The study provides strong evidence supporting the widespread implementation of vitamin A supplementation programs.
  • Early discontinuation of the trial due to significant observed benefit underscores the intervention's impact.

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Acne Infection01:27

Acne Infection

Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...